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30-day Mortality in Patients with Early ST
Timing
of ST
Bivalirudin
(n¼2,889)
Heparin  GPI
(n¼2,911)
Relative risk
[95% CI] P-Value*
Acute (24
hrs)
1/36 (2.8%) 1/6 (16.7%) 0.17 [0.01,
2.16]
0.14
Subacute
(1-30d)
3/25 (12.0%) 15/34 (44.1%) 0.29 [0.10,
0.88]
0.01
Early
(30d)
4/60 (6.7%) 16/40 (40.0%) 0.19 [0.07,
0.52]
0.0002
*Cochran-Mantel-Haenszel c2 test stratiﬁed by study
Unadjusted population
p
PSM population
p
Bivalirudin
N ¼ 4370
UFH
N ¼
19,564
Bivalirudin
N ¼ 3649
UFH
N ¼
3649
% % % %
Death 0.3 1.0 <0.0001 0.3 0.7 0.01
Stroke 0.1 0.3 0.054 0.2 0.3 0.22
MI 0.6 1.2 0.0004 0.5 0.8 0.25
Amputation 1.3 4.5 <0.0001 1.5 2.0 0.09
Transfusion 3.4 10.0 <0.0001 4.0 5.3 0.009
MACE 2.2 6.6 <0.0001 2.3 3.5 0.003
NACE 5.4 14.8 <0.0001 5.9 7.9 0.0009
Association Between Activated Clotting Time (per 50 sec increase) and
Clinical Outcome
Unadjusted OR
(95% CI) p value
Adjusted OR
(95% CI)
p
value
In hospital overt
bleeding
0.94 (0.88, 1.01) 0.09 1.00 (0.93, 1.08) 0.96
In hospital death 0.79 (0.71, 0.88) <0.0001 1.01 (0.89, 1.15) 0.85
In hospital death/MI 0.98 (0.93, 1.04) 0.51 1.01 (0.95, 1.08) 0.77
1 year cardiac
death/MI
0.97 (0.93, 1.01) 0.16 1.00 (0.95, 1.04) 0.81
1 year cardiac
death/MI/TLR
0.97 (0.94, 1.00) 0.07 0.99 (0.96, 1.03) 0.57
Abbreviations: MI, myocardial infarction; TLR, target lesion revascularization
Models adjusted for age, sex, body mass index, hypertension, diabetes, heart failure, smoking,
cholesterol level, prior PCI/CABG, shock at presentation, MI at presentation, stent type (drug
eluting vs bare metal), glycoprotein IIb/IIIa use
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: This analysis from a very large US hospital database suggests that the
use of bivalirudin anticoagulation for PAI may confer signiﬁcant clinical beneﬁts over
heparin. These results require conﬁrmation in a prospective randomized trial.
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Background: Controversy exists regarding the optimal choice of anticoagulation
regimen for percutaneous coronary intervention (PCI). We performed a meta-analysis
of randomized controlled trials (RCT) to compare bivalirudin (bival) versus heparin
with provisional or routine glycoprotein IIb/IIIa inhibitor (GPI) use on 30-day out-
comes following PCI.
Methods: Medline/Pubmed and Cochrane CENTRAL were searched along with
recent abstract presentations at national meetings for all RCTs comparing BIV with
provisional GPI use versus heparin with provisional or routine GPI use for PCI.
Pooled estimates of 30 day outcomes were generated for with random-effect models to
compare the treatment groups. Data is presented as odds ratios (OR) [95% conﬁdence
intervals].
Results: Our analysis included 14 studies with 30,446 patients that were randomized
to either bivalirudin with provisional GPI use (n¼14,869) or heparin with provisional
GPI use (n¼6,451) or heparin with routine GPI use (n¼9,126). There was no sig-
niﬁcant difference between anticoagulation with bival compared with heparin for 30
day death (OR 0.94 [0.78-1.14]) or myocardial infarction (OR 1.11 [0.97-1.27]). Early
stent thrombosis was signiﬁcantly greater with bivalirudin compared with heparin (OR
1.62 [1.18-2.23], p¼0.003), especially when comparing bivalirudin versus heparin
with provisional GPI use (OR 2.09 [1.26-3.47], p¼0.005) or among STEMI patients
(OR 2.17 [1.15-4.10], p¼0.02). However, bivalirudin reduced the risk of major bleed
(OR 0.58 [0.49-0.69], p< 0.0001) and TIMI major bleeding (OR 0.58 [0.47-0.71], p<
0.0001) compared with heparin. Meta-regression analysis demonstrated that bleeding
risk with use of heparin signiﬁcantly increases with increasing GPI use (p¼0.02).
Conclusions: Meta-analysis of 14 RCTs with 30,446 patients demonstrated that
bivalirudin is associated with higher risk of stent thrombosis but lower risk of major
bleeding compared with heparin.
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Background: The risk of early (30 day) stent thrombosis (ST) is considerable after
primary PCI for STEMI. We sought to determine the independent predictors of early
ST and evaluate the risk of mortality after ST according to antithrombotic therapy
used during the index primary PCI.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhMethods: In a patient-level pooled analysis from the HORIZONS-AMI and EURO-
MAX trials, we studied 5,800 patients undergoing primary PCI at 188 sites, random-
ized to either bivalirudin or heparin a glycoprotein IIb/IIIa inhibitor (GPI). Predictors
of ST were determined by multivariate logistic regression, and 30-day mortality was
evaluated according to timing of ST and antithrombotic treatment received.
Results: Of 100 patients (1.7%) who developed early ST, 20 (20%) died within 30 days
of enrollment. By logistic regression, independent predictors of early ST were pre-PCI
TIMI grade ﬂow 0-1 and Killip class 2 at presentation. Bivalirudin was associated
with higher rates of early ST (2.1% vs. 1.4%, RR¼1.51, adj. p-value¼0.07) driven by a
higher incidence of acute ST (1.2% vs. 0.2%, RR¼6.04, p< 0.0001) with similar rates
of subacute ST (0.9% vs. 1.2%, RR¼0.74, p¼0.24) in comparison to heparin  GPI.
However, 30-day mortality rates among patients with ST were lower in the bivalirudin-
treated subset; this was consistent for both acute and subacute ST (Table). As a result,
only 4/2,889 bivalirudin-treated patients died within 30 days after early ST compared
to 16/2,911 heparin  GPI treated patients (0.14% vs. 0.56% respectively, P¼0.01).
Conclusions: Killip class 2 during acute MI presentation and pre-procedure TIMI
grade ﬂow 0-1 are independent predictors of early ST after primary PCI. Although the
risk of ST within 30 days is higher among patients treated with bivalirudin due to a
greater hazard of acute ST, death attributable to early ST is substantially less common
in patients having received bivalirudin compared to heparin  GPI.TCT-469
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Background: Monitoring the intensity of anticoagulation with heparin during
percutaneous coronary intervention (PCI) using the activated clotting time (ACT) is
one of the most frequently used tests in invasive cardiology. However, despite its
ubiquitous use, controversy remains regarding the association of ACT with ischemic
and bleeding events.
Methods: We reviewed all PCI procedures performed at Mayo Clinic (Rochester,
MN) between 2001 - 2012 and evaluated the association between the ACT value at the
time of PCI and in-hospital and 1-year outcomes. For descriptive purposes, ACT
values were grouped into tertiles. We used logistic and Cox proportional hazards
regression models to estimate the association of ACT, modeled continuously, with
outcomes while accounting for baseline characteristics.
Results: Of 12,059 patients studied, 3,978 (33.0%) had ACT < 227, 4,047 (33.6%) had
ACT227-285, and 4,034 (33.4%)hadACT>285.Groupswere similar regarding baseline
and procedural characteristics. In univariate analysis, ACT had associations with in-hos-
pital and 1-year clinical events; however, after multivariable adjustment, ACT at the time
of device activation was not independently associated with outcomes (Table).armacotherapy - Procedural Anticoagulants B137
